The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA.

ABSTRACT:

Purpose

Oncogenic kinase fusions are targetable with approved and investigational therapies and can also mediate acquired resistance (AR) to targeted therapy. We aimed to understand the clinical validity of liquid biopsy comprehensive genomic profiling (CGP) to detect kinase fusions pan tumor.

Experimental design

CGP was performed on plasma and tissue samples during clinical care. All exons plus selected introns of 16 kinases involved in oncogenic fusions (ALK, BRAF, EGFR, ERBB2, FGFR1/2/3, MET, NTRK1/2/3, PDGFRA/B, RAF1, RET, and ROS1) were sequenced to capture fusions, including well-characterized and novel breakpoints. Plasma circulating tumor DNA (ctDNA) fraction was estimated to inform sensitivity.

Results

Of 36,916 plasma cases, 32,492 (88%) had detectable ctDNA

SUBMITTER: Lee JK 

PROVIDER: S-EPMC9377769 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature